Skip NavigationSkip to Content

Dr. Craig Thomas



Dr. Craig Thomas
Chemistry Technology
301-217-4079

Research Summary

For more information about Chemistry Technology at NCATS, please go to: http://www.ncats.nih.gov/research/reengineering/ncgc/chemtech/chem-tech.html
PublicationsPatents
1 - 5 of 143 results

1)  Zanos P, Moaddel R, Morris PJ, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD.
Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.
Biol. Psychiatry. 81: e69-e71, 2017. [Journal]

2)  Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD.
Zanos et al. reply.
Nature. 546: E4-E5, 2017. [Journal]

3)  Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Cancer Cell. 31: 833-843.e5, 2017. [Journal]

4)  Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song YK, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J.
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Cancer Discov. 2017. [Journal]

5)  Munjal C, Jegga AG, Opoka AM, Stoilov I, Norris RA, Thomas CJ, Smith JM, Mecham RP, Bressan GM, Hinton RB.
Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model.
Physiol Rep. 5, 2017. [Journal]